Mily will be leading the company strategy and all business development activities. This includes overseeing strategic partnerships, mergers and acquisitions, etc.
Bristol Myers Squibb announced the appointment of Elizabeth Mily as Executive Vice President, Strategy & Business Development on Wednesday.
Mily will be leading the company strategy and all business development activities. This includes overseeing strategic partnerships, mergers and acquisitions, etc.
“I look forward to playing an important role in enhancing our capability to pursue the next generation of medicines, " Mily said in a statement posted on the company’s Twitter account.
Before accepting the new position at Bristol Myers Squibb, Mily had made tremendous accomplishments in her previous job at Barclays, where she was Managing Director and Chair of the Global Lifesciences group in the global healthcare unit. She completed M&A advisory assignments worth over $200 billion and advised on large debts and equity-linked financing.
Prior to Barclays, Mily also worked for Thermo Fisher Scientific as Head of Corporate Strategy and Development and spent 16 years at Goldman, Sach & Co. where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division.
“I am excited to welcome her to Bristol Myers Squibb as we position the company for continued growth through high performing brands, upcoming new product launches, an exciting pipeline, and the financial strength to pursue innovation for the next wave of new medicines,” said Bristol Myers CEO Giovanni Caforio.
In her role, she will report to Caforio and be a new member of the Bristol Myers Squibb leadership team.
“Elizabeth is an accomplished leader in investment banking and health care M&A, and I look forward to the important role she will play in sourcing external innovation to drive our vision of transforming patients’ lives through science,” Caforio said.
The news comes following the release of Bristol Myers Squibb’s response to the COVID-19 outbreak. In a press release, the company states they have restricted business travel, in-person meetings, encouraging employees to work from home if able and other precautionary measures. There has been no comment on if or how this might affect Mily’s transition into the new position, which is to take effect on March 30th, 2020.
The company, primarily focused on research and development of pharmaceuticals and biologics, has been putting forth efforts to contribute to COVID-19 relief with education and patient resources.
